Welcome to our dedicated page for Inspira Tech SEC filings (Ticker: IINNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inspira Technologies Oxy B.H.N. Ltd. filings document a foreign private issuer reporting on Form 6-K and incorporating selected reports by reference into Form F-3 and Form S-8 registration statements. Recent disclosures cover shareholder communications, strategic direction, shareholder meeting results, proxy voting matters, registration-statement references, and governance records.
The filings also describe company activity across its medical business and newer technology initiatives, including the INSPIRA™ ART100 life-support platform, the HYLA™ blood sensor, an Additively Manufactured Electronics platform branded QTREX, and quantum-connectivity applications such as cryogenic interconnect structures for superconducting quantum systems. Formal reports include material agreements, purchase-order disclosures, capital-structure context, and risk-related business updates tied to these operating areas.
Qtrex Quantum Ltd., formerly Inspira Technologies Oxy B.H.N. Ltd., reports that shareholders approved a corporate name change, which became effective on May 10, 2026 with the Israeli Registrar of Companies. The company plans to begin trading on the Nasdaq Capital Market under the new ticker symbol “QTEX” for its ordinary shares and “QTEXW” for its warrants at the opening of trading on May 20, 2026, replacing “IINN” and “IINNW.” The filing emphasizes that the name and ticker changes do not alter shareholder rights, company status, or the validity and transferability of existing share certificates, and no shareholder action is required. The accompanying press release explains that the new name highlights a strategic focus on the company’s Additively Manufactured Electronics platform for advanced manufacturing, high-performance electronics, and quantum connectivity, while it continues to develop and monetize parts of its medical technology portfolio.
Qtrex Quantum Ltd., formerly Inspira Technologies Oxy B.H.N. Ltd., reports that shareholders approved a corporate name change, which became effective on May 10, 2026 with the Israeli Registrar of Companies. The company plans to begin trading on the Nasdaq Capital Market under the new ticker symbol “QTEX” for its ordinary shares and “QTEXW” for its warrants at the opening of trading on May 20, 2026, replacing “IINN” and “IINNW.” The filing emphasizes that the name and ticker changes do not alter shareholder rights, company status, or the validity and transferability of existing share certificates, and no shareholder action is required. The accompanying press release explains that the new name highlights a strategic focus on the company’s Additively Manufactured Electronics platform for advanced manufacturing, high-performance electronics, and quantum connectivity, while it continues to develop and monetize parts of its medical technology portfolio.
Inspira Technologies Oxy B.H.N. Ltd. furnished a report highlighting a new commercial milestone for its ART100 system. NYU Langone Hospital in New York City issued a $580,000 purchase order for Inspira’s FDA-cleared ART100 extracorporeal blood circulation systems following a multi-patient hospital evaluation.
The evaluation involved using ART100 in the treatment of more than 30 patients across varied cardiopulmonary and surgical cases, giving NYU Langone operational experience with the platform and leading to its decision to move from clinical assessment to commercial procurement. Inspira notes that this order provides an important hospital reference as it continues commercial discussions with additional U.S. and international hospitals and pursues an active strategic process involving potential transactions related to the ART100 system and other medical assets.
Inspira Technologies Oxy B.H.N. Ltd. furnished a report highlighting a new commercial milestone for its ART100 system. NYU Langone Hospital in New York City issued a $580,000 purchase order for Inspira’s FDA-cleared ART100 extracorporeal blood circulation systems following a multi-patient hospital evaluation.
The evaluation involved using ART100 in the treatment of more than 30 patients across varied cardiopulmonary and surgical cases, giving NYU Langone operational experience with the platform and leading to its decision to move from clinical assessment to commercial procurement. Inspira notes that this order provides an important hospital reference as it continues commercial discussions with additional U.S. and international hospitals and pursues an active strategic process involving potential transactions related to the ART100 system and other medical assets.
Inspira Technologies OXY B.H.N. Ltd files an amendment to its Schedule 13G/A reporting that Joe Ronen Hayon beneficially owns 2,544,474 ordinary shares, equal to 5.7% of the company's outstanding ordinary shares. The filing states the ownership comprises 656,081 ordinary shares and 1,888,393 ordinary shares vested pursuant to issued and outstanding restricted stock units. The percentage is calculated on 44,473,260 outstanding shares. The signature block shows the amendment was signed on 05/15/2026.
Inspira Technologies OXY B.H.N. Ltd files an amendment to its Schedule 13G/A reporting that Joe Ronen Hayon beneficially owns 2,544,474 ordinary shares, equal to 5.7% of the company's outstanding ordinary shares. The filing states the ownership comprises 656,081 ordinary shares and 1,888,393 ordinary shares vested pursuant to issued and outstanding restricted stock units. The percentage is calculated on 44,473,260 outstanding shares. The signature block shows the amendment was signed on 05/15/2026.
INSPIRA TECHNOLOGIES OXY B.H.N. LTD. reports that Armistice Capital, LLC and Steven Boyd collectively beneficially own 4,343,252 ordinary shares, representing 9.99% of the outstanding ordinary shares. The filing states Armistice Capital exercises shared voting and dispositive power over those shares under an Investment Management Agreement.
INSPIRA TECHNOLOGIES OXY B.H.N. LTD. reports that Armistice Capital, LLC and Steven Boyd collectively beneficially own 4,343,252 ordinary shares, representing 9.99% of the outstanding ordinary shares. The filing states Armistice Capital exercises shared voting and dispositive power over those shares under an Investment Management Agreement.
Inspira Technologies is reshaping its strategy around three value tracks: a commercially active Additively Manufactured Electronics (AME) platform, a focused quantum connectivity program, and a repositioned medical business. Management expects recent commercial activity to mark the start of a broader revenue ramp supported by AME system sales, recurring consumables and service revenues, and monetization of medical technologies.
The Company reports more than $1 million from recent AME-related transactions, with most already received in cash, early deployments at a Tier-1 U.S. defense customer and a “Magnificent Seven” technology company, and a joint development agreement with Qarakal Quantum to validate its monolithic quantum connectivity architecture. The medical segment is being prepared for partial sale, backed by FDA-cleared ART100 usage in over 40 patients and planned FDA submission for the HYLA platform, with a goal of reaching at least a term sheet by the end of the third quarter of 2026.
Inspira is also moving to change its name to QTREX Quantum Ltd., has reduced medical business burn, terminated its ATM and SEPA facilities in March 2026, and emphasizes disciplined capital allocation aimed at preserving cash, extending runway, and translating strategic progress into measurable financial results.
Inspira Technologies is reshaping its strategy around three value tracks: a commercially active Additively Manufactured Electronics (AME) platform, a focused quantum connectivity program, and a repositioned medical business. Management expects recent commercial activity to mark the start of a broader revenue ramp supported by AME system sales, recurring consumables and service revenues, and monetization of medical technologies.
The Company reports more than $1 million from recent AME-related transactions, with most already received in cash, early deployments at a Tier-1 U.S. defense customer and a “Magnificent Seven” technology company, and a joint development agreement with Qarakal Quantum to validate its monolithic quantum connectivity architecture. The medical segment is being prepared for partial sale, backed by FDA-cleared ART100 usage in over 40 patients and planned FDA submission for the HYLA platform, with a goal of reaching at least a term sheet by the end of the third quarter of 2026.
Inspira is also moving to change its name to QTREX Quantum Ltd., has reduced medical business burn, terminated its ATM and SEPA facilities in March 2026, and emphasizes disciplined capital allocation aimed at preserving cash, extending runway, and translating strategic progress into measurable financial results.
Inspira Technologies Oxy B.H.N. Ltd. held an Extraordinary General Meeting of Shareholders on May 6, 2026. The meeting was initially adjourned at 12:00 p.m. Israel time for lack of quorum but reconvened at 1:30 p.m., when a quorum was present.
At the adjourned meeting, shareholders approved the single agenda item described in the company’s earlier notice and proxy statement filed on April 16, 2026. The company also states that this report is incorporated by reference into its existing registration statements on Forms F-3 and S-8.
Inspira Technologies Oxy B.H.N. Ltd. held an Extraordinary General Meeting of Shareholders on May 6, 2026. The meeting was initially adjourned at 12:00 p.m. Israel time for lack of quorum but reconvened at 1:30 p.m., when a quorum was present.
At the adjourned meeting, shareholders approved the single agenda item described in the company’s earlier notice and proxy statement filed on April 16, 2026. The company also states that this report is incorporated by reference into its existing registration statements on Forms F-3 and S-8.
Inspira Technologies OXY B.H.N. Ltd. entered a Joint Development Agreement with Qarakal Quantum, a superconducting quantum computing company, to develop and test cryogenic interconnect solutions for quantum systems. The collaboration uses Inspira’s QTREX Additively Manufactured Electronics platform inside Qarakal’s superconducting quantum environment.
The agreement sets a structured, multi-phase engineering program in which Qarakal defines technical requirements and success metrics, while Inspira supplies 3D‑printed conductive and insulating structures for evaluation at milli‑Kelvin temperatures. This initiative marks a strategic expansion of Inspira’s quantum connectivity business alongside its existing respiratory support and blood monitoring medical technology portfolio.
Inspira Technologies OXY B.H.N. Ltd. entered a Joint Development Agreement with Qarakal Quantum, a superconducting quantum computing company, to develop and test cryogenic interconnect solutions for quantum systems. The collaboration uses Inspira’s QTREX Additively Manufactured Electronics platform inside Qarakal’s superconducting quantum environment.
The agreement sets a structured, multi-phase engineering program in which Qarakal defines technical requirements and success metrics, while Inspira supplies 3D‑printed conductive and insulating structures for evaluation at milli‑Kelvin temperatures. This initiative marks a strategic expansion of Inspira’s quantum connectivity business alongside its existing respiratory support and blood monitoring medical technology portfolio.
Inspira Technologies Oxy B.H.N. Ltd. reported a fully paid $390,000 purchase order for its additive manufacturing electronics (AME) system from a premier Asia-Pacific technological research university focused on quantum computing.
The order was prepaid before shipment and is structured to generate ongoing recurring revenue from consumables and annual service fees. Inspira plans to deliver and deploy the AME system in the coming weeks, along with advanced application training for the university’s quantum research teams.
Inspira Technologies Oxy B.H.N. Ltd. reported a fully paid $390,000 purchase order for its additive manufacturing electronics (AME) system from a premier Asia-Pacific technological research university focused on quantum computing.
The order was prepaid before shipment and is structured to generate ongoing recurring revenue from consumables and annual service fees. Inspira plans to deliver and deploy the AME system in the coming weeks, along with advanced application training for the university’s quantum research teams.
Inspira Technologies OXY B.H.N. Ltd filed an initial Form 3 for Chief Business Officer Yoav Rozanovich. This statement of beneficial ownership, based on the provided data, shows no reported common stock or derivative holdings and records no buy, sell, gift, or option exercise activity.
Inspira Technologies OXY B.H.N. Ltd filed an initial Form 3 for Chief Business Officer Yoav Rozanovich. This statement of beneficial ownership, based on the provided data, shows no reported common stock or derivative holdings and records no buy, sell, gift, or option exercise activity.
Inspira Technologies OXY B.H.N. Ltd. reports the successful commercial delivery and acceptance of its Additively Manufactured Electronics (AME) system at a Tier-1 U.S. defense customer site under a commercial agreement. The customer operates in advanced areas such as quantum computing, quantum networking, integrated photonics, and superconducting systems, where complex integration and extreme miniaturization are critical.
The engagement includes ongoing supply of proprietary consumables and materials, creating a contractual basis for recurring revenue beyond the initial system sale, with added potential from application-specific adaptations as usage grows. Management describes this deployment as tangible commercial execution of Inspira’s AME strategy in a top-tier defense environment and views it as evidence of commercial demand for the platform. Inspira is focused on quantum connectivity hardware while continuing to advance its medical technology portfolio.
Inspira Technologies OXY B.H.N. Ltd. reports the successful commercial delivery and acceptance of its Additively Manufactured Electronics (AME) system at a Tier-1 U.S. defense customer site under a commercial agreement. The customer operates in advanced areas such as quantum computing, quantum networking, integrated photonics, and superconducting systems, where complex integration and extreme miniaturization are critical.
The engagement includes ongoing supply of proprietary consumables and materials, creating a contractual basis for recurring revenue beyond the initial system sale, with added potential from application-specific adaptations as usage grows. Management describes this deployment as tangible commercial execution of Inspira’s AME strategy in a top-tier defense environment and views it as evidence of commercial demand for the platform. Inspira is focused on quantum connectivity hardware while continuing to advance its medical technology portfolio.